Literature DB >> 20691212

Repertoire of antibodies against type 1 poliovirus in human sera.

Gennady Rezapkin1, Alexander Neverov, Elena Cherkasova, Emmanuel Vidor, Andrei Sarafanov, Diana Kouiavskaia, Eugenia Dragunsky, Konstantin Chumakov.   

Abstract

A blocking-ELISA procedure was used to quantify antibodies in sera of humans immunized with poliovirus vaccines. Titers determined by this method demonstrated an excellent correlation with the results of neutralization test. Testing of serum potency with a panel of type 1 poliovirus strains altered antigenically was used to evaluate the composition of polyclonal sera with respect to the epitope specificity of constituent antibodies. Paratope profiles of various polyclonal sera determined by this new method differed, depending on the type of vaccine used for immunization. Antibodies induced in response to inactivated poliovirus vaccine (IPV) contained antibodies directed primarily against antigenic site 1, while sera from recipients of the oral poliovirus vaccine (OPV) contained antibodies to site 3. Antibodies to antigenic sites 2 and 4 were minor constituents in both types of sera. Pre-immunization sera had paratope profiles similar to OPV-induced antisera, allowing the discrimination between antibodies induced by IPV and maternal antibodies. The new method may be useful for analyzing results of clinical trials and to compare immunity induced by different poliovirus vaccines. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691212     DOI: 10.1016/j.jviromet.2010.07.037

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.

Authors:  Minetaro Arita; Masae Iwai; Takaji Wakita; Hiroyuki Shimizu
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

2.  Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Authors:  Zhaochun Chen; Konstantin Chumakov; Eugenia Dragunsky; Diana Kouiavskaia; Michelle Makiya; Alexander Neverov; Gennady Rezapkin; Andrew Sebrell; Robert Purcell
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

3.  Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Authors:  Jan Felix Drexler; Gilda Grard; Alexander N Lukashev; Liubov I Kozlovskaya; Sindy Böttcher; Gökhan Uslu; Johan Reimerink; Anatoly P Gmyl; Raphaël Taty-Taty; Sonia Etenna Lekana-Douki; Dieudonné Nkoghe; Anna M Eis-Hübinger; Sabine Diedrich; Marion Koopmans; Eric M Leroy; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

4.  Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.

Authors:  Pamela A Opperman; Lia S Rotherham; Jan Esterhuysen; Bryan Charleston; Nicholas Juleff; Alejandra V Capozzo; Jacques Theron; Francois F Maree
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.